UK investor profile and portfolio
Syncona
4 UK company relationship(s) retained from funding evidence.
0 as lead
UK portfolio companies
- Beacon TherapeuticsLondon
- OMass TherapeuticsSouth East
- Purespring TherapeuticsLondon
- Quell TherapeuticsLondon
Sources
- https://www.prnewswire.com/news-releases/beacon-therapeutics-raises-170-million-in-series-b-funding-to-advance-development-of-ophthalmic-gene-therapies-302188599.html
- https://www.massbio.org/members/beacon-therapeutics/
- https://www.uktech.news/medtech/omass-therapeutics-10m-20230515
- https://thebusinessmagazine.co.uk/companies/oxford-spin-out-omass-raises-75million-in-financing-round/
- https://www.globenewswire.com/news-release/2024/10/09/2960230/0/en/Purespring-Therapeutics-raises-80-105-million-in-a-Series-B-financing-to-transform-the-treatment-of-kidney-diseases.html
- https://www.fiercebiotech.com/biotech/purespring-bottles-105m-series-b-bring-kidney-disease-gene-therapy-clinic
- https://www.prnewswire.com/news-releases/quell-therapeutics-raises-156-million-in-oversubscribed-series-b-financing-to-advance-its-pioneering-multi-modular-engineered-t-regulatory-treg-cell-therapy-pipeline-and-platform-301432188.html
- https://www.insideprecisionmedicine.com/news-and-features/quell-therapeutics-well-placed-to-advance-treg-cell-therapy-platform-with-156m-series-b/